Clinical research of liposome paclitaxel combined with nedaplatin in treatment of advanced non-small cell lung cancer
10.3760/cma.j.issn.1006-9801.2013.12.004
- VernacularTitle:紫杉醇脂质体联合奈达铂治疗晚期非小细胞肺癌的临床研究
- Author:
Haiqing LUO
;
Chengnong GUAN
;
Zihong CHEN
;
Donghong YANG
;
Zhonghua YU
- Publication Type:Journal Article
- Keywords:
Liposome;
Paclitaxel;
Nedaplatin;
Carcinoma,non-small-cell lung;
Drug therapy,combination
- From:
Cancer Research and Clinic
2013;25(12):803-805
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy,overall survival and toxicities in the patients with advanced non-small cell lung cancer treated by liposome paclitaxel combined with nedaplatin as first-line treating.Methods 34 cases with advanced NSCLC were treated with liposome paclitaxel 150 mg/m2 on day 1 and nedaplatin 80 mg/m2 on day 1 by intravenous infusion,with 21 days as one cycle.The patients were treated with chemotherapy more than 2 cycles.Efficacy evaluation and adverse events were evaluated every 2 cycles.Results 34 patients were available for evaluation of efficacy and adverse events.The patients recieved 174 cycles of chemotherapy,and the median was 5.3 cycles.The objective response rate of liposome paclitaxel combined with nedaplatin was 32.3 ％,the disease control rate was 67.6 ％,the median overall survival was 9.5 months (95 ％ CI 6.2-10.7),1 years survival rate was 40.6 ％.The main adverse events were hematological and gastrointestinal toxicities.Frequent grade Ⅲ-Ⅳ toxicities included neutropenia (41.7 ％),anemia (17.6 ％),thrombocytopenia (8.8 ％),nausea and vomiting (8.8 ％),diarrhea (5.8 ％).Conclusions The regimen of liposome paclitaxel combined with nedaplatin is against advanced non-small cell lung cancer with high efficacy and acceptable toxicities,and it may be used as a new choice for treatment of advanced non-small cell lung cancer.
